serge verstovsek, md on the phase 2 study involving ruxolitinib with azacytidine
Published 7 years ago • 117 plays • Length 1:36Download video MP4
Download video MP3
Similar videos
-
1:29
serge verstovsek, md on myelofibrosis
-
7:29
serge verstovsek, md on myelofibrosis and thrombocytosis (full interview)
-
4:32
5-azacytidine in combination with ruxolitinib as therapy for patients with mds/mpn
-
31:14
update on jak2 inhibitors by srdan verstovsek, md
-
2:19
dr. verstovsek on toxicity profile of ruxolitinib in mpns
-
1:19
dr. srdan verstovsek on jak2 inhibitors as a treatment for myelofibrosis
-
0:32
enrica marci, md discusses the need for creativity in orphan disease diagnosis
-
31:14
update on jak2 inhibitors by srdan verstovsek, md
-
24:31
managing myelofibrosis in 2021 - dr. srdan verstovsek
-
2:00
genetic mutations and inflammation: understanding the links and improving prognosis in mds
-
16:18
mseqdr and mitochondrial disease data resources
-
2:01
rare disease scleroderma strikes about 300,000 americans
-
1:44
binswager disease
-
2:16
dr. verstovsek on limitations of the current treatment landscape of myelofibrosis
-
3:01
scleroderma by w. leroy griffing, m.d. | preview
-
1:49
dr. philip robinson on scleroderma complications
-
2:26
scleroderma associated myopathy - overview | johns hopkins
-
3:56
expanding neuropalliative care to new disease states
-
6:39
recurrance of diseases